Sotrovimab | EUA revocation information for HCPs

For US HCPs

For US Healthcare Professionals

Important Update: As of December 13, 2024, the emergency use authorization for sotrovimab has been revoked by the FDA. See below for the FDA revocation letter as well as a letter to facilities and healthcare providers. For additional information please see the FDA website.

FDA Revocation Letter

Informational Letter from GSK to facilities and healthcare providers

To report SUSPECTED ADVERSE REACTIONS, contact GSK at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

This is my caption

Trademarks are owned by or licensed to the GSK group of companies.